Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast.

In this episode Tim interviews Steven Yatomi-Clarke, CEO and managing director at Prescient Therapeutics (ASX:PTX).

Prescient is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted therapies, cell therapy enhancements and next generation CAR-T therapies.

Encouraging progress through clinical trials of Prescient’s foundational assets PTX-100 and PTX-200 (with the PTX-100 trial progressing to expansion cohort last week following successful Phase 1b) and CAR-T safety and manufacturing milestone with OmniCAR.

The company made headlines in late July with news of its strong finish to the June quarter.

So tune in below to hear about Prescient’s latest developments and forward plan.

On mobile? Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.

Like to listen to podcasts through another app? Just search for The Health Kick Podcast with Tim Boreham and subscribe!

Read MoreDrug DevelopmentHealthMedtech

Featured Companies

You might be interested in